Submitted by Ed Marcuse

Two new studies involving more than 1 million US veterans suggest that updated COVID-19 vaccines continue to provide meaningful protection against severe illness.
One study, published last week in Vaccine, found that the 2025–26 vaccine reduced the risk of emergency department visits by approximately 32% and the risk of hospitalization by roughly 44%. The second study, published last week in JAMA Network Open, found that the 2025–26 Moderna vaccine offered greater protection against medically attended COVID among older adults than Pfizer’s vaccine.
Vaccination tied to fewer emergency visits, hospitalizations
In the first study, a team led by researchers from Veterans Affairs (VA) Saint Louis Health Care System analyzed data from 931,943 veterans who received a seasonal flu vaccine from September 21, 2025, to January 31, 2026. Of those, 114,911 received a COVID vaccine on the same day, while 817,032 received only the flu vaccine.
Over the course of 180 days, COVID vaccination was associated with a 31.7% reduction in COVID-related emergency department (ED) visits and a 43.6% decrease in hospitalizations. That translates to approximately seven fewer ED visits and roughly three fewer hospitalizations per 10,000 people.
While the researchers note that the absolute risk reductions were modest, the findings “quantify the benefit of vaccination in a lower-incidence season and can inform shared clinical decision making and seasonal vaccine policy,” they write.
Moderna vaccine outperforms Pfizer’s version
For the second study, researchers led by a team from VA Providence Healthcare System in Rhode Island compared Moderna’s newer mRNA-1283 COVID vaccine with Pfizer/BioNTech’s mRNA COVID vaccine among US veterans aged 65 years or older to assess whether 2025–26 vaccination was associated with a lower risk of COVID infection that required medical attention.
Among the 294,499 participants, medically attended COVID occurred in 86 of 55,349 mRNA-1283 vaccine recipients (0.16%) and 672 of 239,150 Pfizer vaccine recipients (0.28%). That corresponds to a 35.9% greater relative vaccine effectiveness (VE) for the Moderna vaccine, or 10 fewer medically attended cases per 10,000 vaccinated people.